CTSO and breast carcinoma: This was consistent with our previous finding that the odds ratios for CTSO V/ZNF423 W (OR = 5.71) was the highest, and that for CTSO WT/ZNF423 V (OR = 1.00) was the lowest for breast cancer risk in the P-1, P-2 trials [20].